Alzheimer's Screening

Harnessing cutting-edge Digital Immunochip technology, these kits enable the precise quantification of Beta-Amyloid (1-40 and 1-42) at the femtogram level. A non-invasive solution designed to assess cortical amyloid burden and cognitive decline risk through the Aβ42/40 ratio—a key metric highly correlated with amyloid PET positivity.

Delivering 1,000x greater sensitivity than conventional assays, the iomics GFAP Detection Kit (Digital Immunochip Method) enables precise quantification of astrocyte activation directly from blood samples. It provides a superior, non-invasive diagnostic solution for differentiating Alzheimer’s Disease (AD) from other cognitive disorders and monitoring pathological progression through amyloid burden and neuronal loss.

Harnessing revolutionary Digital Immunochip technology, this kit delivers 1,000x greater sensitivity than traditional assays for quantifying Neurofilament Light chain (NfL) in human plasma. A non-invasive diagnostic tool essential for monitoring neurodegeneration, brain atrophy, and clinical progression in Alzheimer's (AD), Multiple Sclerosis (MS), and Traumatic Brain Injury (TBI).

The Human p-Tau181 Protein Detection Kit (Digital Immunochip Method) by iomics Biosciences is a cutting-edge auxiliary diagnostic tool for Alzheimer’s disease. Delivering 1,000x higher sensitivity than traditional ELISA, it enables precise quantification of p-Tau181 in human plasma at femtogram levels, identifying pathological biomarkers 10-20 years before clinical symptoms manifest.

Powered by proprietary Digital Immunochip technology, the iomics p-Tau217 kit delivers diagnostic accuracy comparable to Cerebrospinal Fluid (CSF) biomarkers through a non-invasive blood test. With femtogram-level sensitivity, it enables precise Alzheimer’s Disease (AD) pathology identification in the pre-dementia stage, empowering clinicians and researchers with absolute data confidence.

Optimized for the Inspirer DX platform, the Human p-Tau231 Detection Kit (Digital Immunochip Method) provides a reliable, objective quantitative measure of p-Tau231 levels in human plasma. Classified as a core Alzheimer’s Disease (AD) fluid biomarker, it empowers clinicians to identify and manage disease progression with unprecedented precision at the femtogram level.

The Inspirer DX Analyzer is a groundbreaking diagnostic platform that redefines precision in biomarker detection. Surpassing the limitations of traditional methods, the Inspirer DX Analyzer utilizes revolutionary single-molecule immunoassay technology, allowing for the quantification of trace proteins at the femtogram level. It serves as the optimal solution for the early diagnosis of neurological diseases (such as Alzheimer's), cardiovascular conditions, and pharmaceutical research with absolute accuracy.